Group 1 - The core point of the news is that China National Pharmaceutical Group has received approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug, Kumosili Capsule (brand name: Saitanxin), for use in combination with Fulvestrant to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer patients who have previously undergone endocrine therapy [1][2] - Kumosili is a world-first triple inhibitor targeting CDK2/4/6, showing varying degrees of inhibition on CDK2, CDK4, and CDK6 kinases, with a strong selective inhibition capability on CDK4 kinase [1] - The unique mechanism of action of Kumosili helps delay the resistance issues associated with CDK4/6 inhibitors in clinical settings and reduces the risk of bone marrow suppression [1] Group 2 - In the pivotal Phase III clinical trial (TQB3616-III-01), the combination of Kumosili and Fulvestrant demonstrated encouraging efficacy, with a median progression-free survival (mPFS) of 16.62 months, significantly extending the mPFS by 9.16 months compared to the Fulvestrant group (7.46 months), and reducing the risk of disease progression or death by 64% (HR=0.36, p<0.0001) [2] - The objective response rate (ORR) significantly improved to 40.21% compared to 12.12% in the Fulvestrant group (p<0.0001) [2] - The most common treatment-related adverse events (TRAEs) were mostly grade 1-2 and manageable; grade 3 or higher hematological toxicities, such as bone marrow suppression, were low; no TRAEs led to treatment discontinuation or death, indicating overall safety and tolerability [2] - In addition to the approved second-line treatment indication, a first-line HR+/HER2- breast cancer indication for Kumosili in combination with Fulvestrant has been submitted to NMPA for approval in July 2025, and the Phase III clinical trial for its adjuvant treatment indication has completed patient enrollment, with gradual approvals expected in the next two years [2]

Core Viewpoint - China Biologic Products (01177.HK) has received approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug, Kumosily, for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer patients who have experienced disease progression after endocrine therapy [1][2]. Group 1: Drug Approval and Mechanism - Kumosily is a globally first-in-class triple inhibitor targeting CDK2/4/6, showing selective inhibition of CDK4 kinase, which helps delay resistance to CDK4/6 inhibitors and reduces the risk of bone marrow suppression [1]. - The drug has been approved for use in combination with Fulvestrant for second-line treatment [1]. Group 2: Clinical Trial Results - In the pivotal Phase III clinical trial (TQB3616-III-01), the combination of Kumosily and Fulvestrant demonstrated a median progression-free survival (mPFS) of 16.62 months, significantly extending the mPFS by 9.16 months compared to the Fulvestrant group (7.46 months) [2]. - The risk of disease progression or death was reduced by 64% (HR=0.36, p<0.0001), and the objective response rate (ORR) increased significantly to 40.21% compared to 12.12% (p<0.0001) [2]. - Most treatment-related adverse events (TRAEs) were manageable and of grade 1-2, with minimal grade ≥3 hematological toxicity, and no TRAEs leading to treatment discontinuation or death [2]. Group 3: Future Development and Pipeline - Besides the approved second-line indication, a first-line application for HR+/HER2- breast cancer has been submitted to NMPA, with expectations for approval by July 2025 [3]. - The company has completed patient enrollment for the Phase III clinical trial for the adjuvant treatment indication, aiming for gradual approvals in the next two years [3]. - The company is focused on the breast cancer field, developing a pipeline that covers all molecular subtypes, including HR-positive, HER2-positive, low HER2 expression, and triple-negative breast cancer, with a comprehensive treatment strategy from new adjuvant to later lines [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 「庫莫西利膠囊」獲批上市 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的國家1類創新藥庫莫西利膠囊 (商品名：賽坦欣®) 已獲得中國國家藥品監督管理局 (NMPA) 的上市批准，用於與氟維司群聯合治療既往接受內分泌治療後出現疾病進展的激素受體 (HR) 陽性、 人表皮生長因子受體2 (HER2) 陰性的局部晚期或轉移性乳腺癌患者。 參考文獻： 承董事會命 庫莫西利是全球首創的同時靶向CDK2/4/6的三重抑制劑，對CDK2、CDK4、CDK6激酶有不同程度 的抑制效果，且對CDK4激酶有較強的選擇性抑制能力。基於其獨特的作用機制，庫莫西利不僅有助 於延緩臨床中CDK4/6抑制劑的耐藥問題，還可以減輕骨髓抑制風險[1]。 在關鍵I ...

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the high-volatility Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 1%, potentially ending a four-day losing streak. Notably, this week has seen a net subscription of over 130 million yuan, indicating increased buying interest [1][6]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a cumulative net subscription of over 130 million yuan this week [1][6]. - As of November 30, the ETF's scale reached 2.142 billion yuan, with an average daily trading volume of 458 million yuan since its listing, making it the largest and most liquid among its peers [10]. Group 2: Sector Dynamics - The leading stock, Kangfang Biologics, surged over 6.8%, while other notable stocks like Innovent Biologics and BeiGene also saw gains of over 2% and 1%, respectively [8]. - Kangfang Biologics has received FDA approval to conduct a Phase III clinical trial for its PD-1/CTLA-4 dual-specific antibody, indicating significant advancements in innovative drug development [3][8]. Group 3: Investment Insights - A report from Ping An Securities suggests that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipelines, high-potential single products, and leading technology platforms [3][8]. - The Hong Kong innovative drug sector has been in a correction phase since early September, enhancing the cost-effectiveness of investments in this area [3][8]. Group 4: Index Characteristics - The underlying index for the ETF, the Hang Seng Stock Connect Innovative Drug Select Index, has a significant concentration of leading stocks, with the top ten holdings accounting for over 72% of the index weight [4][9]. - The index is designed to exclude CXO companies, focusing solely on innovative drug developers, which enhances its purity and comprehensiveness [9].

Core Viewpoint - The release of the first commercial insurance innovative drug directory on December 7, 2025, is a focal point for investment discussions in the innovative drug sector, aiming to create new payment channels for high clinical value drugs that exceed basic medical insurance coverage, significantly reducing patient out-of-pocket expenses and enhancing product accessibility and market penetration [1][3]. Group 1: Innovative Drug Directory - The commercial insurance innovative drug directory is designed to open new payment channels for innovative drugs with high clinical value, which are beyond the basic insurance coverage [1][3]. - The directory's implementation is expected to significantly enhance the accessibility and market penetration of innovative drugs, promoting a greater degree of "universal access" [1][3]. - The final selection rate for the directory was approximately 15.7%, highlighting the recognition of differentiated innovative products with significant clinical advantages [1][3]. Group 2: Hang Seng Innovative Drug ETF - The Hang Seng Innovative Drug ETF (520500) is currently the only ETF tracking the Hang Seng Innovative Drug Index, serving as a tool for investors to capitalize on opportunities in the Hong Kong innovative drug sector [1][3]. - As of December 11, 2025, the top five constituents of the index include Kangfang Biotech, China National Pharmaceutical Group, BeiGene, Innovent Biologics, and Kelun-Biotech, reflecting strong R&D capabilities and growth potential [1][3]. - Since December 8, 2025, the ETF has seen a net inflow of 192 million yuan over four consecutive trading days, with its latest share count reaching 1.225 billion and total assets hitting 2.041 billion yuan, both marking new highs since its inception [1][3]. Group 3: Market Outlook - The central economic work conference held on December 10-11, 2025, emphasized "innovation-driven development" as a key task for the upcoming year, aligning with the supportive policy direction for the innovative drug sector [1][3]. - The combination of proactive policy guidance, breakthroughs in payment systems, and maintained liquidity is expected to create a new development opportunity for the Hong Kong innovative drug sector [1][3]. - The high innovation purity of the Hang Seng Innovative Drug ETF (520500) is anticipated to assist investors in seizing the window of opportunity in the Hong Kong innovative drug market [1][3].

Core Viewpoint - The approval of the first global CDK2/4/6 inhibitor, Kumosiliz, by China National Pharmaceutical Group's subsidiary, marks a significant advancement in targeted therapy for HR+/HER2- advanced or metastatic breast cancer in China, positioning the country in the international arena of breast cancer treatment [1][4]. Group 1: Product Approval and Efficacy - Kumosiliz's approval is based on the CULMINATE-1 study, which demonstrated significant improvement in median progression-free survival (PFS) when combined with Fulvestrant compared to Fulvestrant alone, reducing the risk of disease progression or death in HR+/HER2- advanced breast cancer [1][2]. - The unique molecular design of Kumosiliz allows for precise targeting of CDK4 while enhancing binding to CDK2, with a weaker inhibitory effect on CDK6, thereby reducing the risk of bone marrow suppression associated with traditional CDK4/6 inhibitors [1]. Group 2: Market Potential and Strategic Positioning - Analysts have identified Kumosiliz as a potential "blockbuster" drug, with peak sales in China projected to exceed 2 billion yuan [3]. - China National Pharmaceutical Group is expanding Kumosiliz's indications, including first-line treatment for HR+/HER2- advanced breast cancer and adjuvant therapy for HR+ early breast cancer, indicating a strategic approach to capture a larger market share [3]. - The breast cancer treatment market is rapidly growing, and the company is not relying solely on Kumosiliz but is also developing a comprehensive portfolio of therapies across various breast cancer subtypes and treatment stages [3][4]. Group 3: Comprehensive Product Portfolio - The company has established a robust portfolio of foundational drugs for breast cancer, including already marketed products such as Fulvestrant injection and Trastuzumab injection, positioning itself to leverage the launch of Kumosiliz [4]. - With the launch of Kumosiliz, the company is expected to transition from a single product focus to a cluster of breakthrough products in the breast cancer treatment space, supported by a full-spectrum product matrix covering all molecular subtypes and treatment cycles [4].

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The Hang Seng Technology Index fell by 0.83%, with a market turnover of HKD 182.48 billion [1] - In the US market, the Dow Jones increased by 1.34% to a record high of 48,704.01 points, while the S&P 500 rose by 0.21% [2] Investment Opportunities - The report emphasizes the attractiveness of low-valuation, high-dividend sectors in the Hong Kong market, suggesting that these areas remain appealing for capital allocation [3] - Key sectors to focus on include artificial intelligence, semiconductors, industrial software, and state-owned enterprises with low valuations and high dividends [3] - The report highlights the potential for long-term growth in technology sectors, particularly in companies leading in semiconductors and robotics [3] Company Performance - Meituan-W and Xiaomi Group-W saw increases of 1.50% and 0.96% respectively, while Hua Hong Semiconductor and Horizon Robotics experienced declines of 4.80% and 3.34% [1] - Oracle's stock dropped nearly 11% following concerns over high valuations in the tech sector, despite the overall market benefiting from the Federal Reserve's interest rate cuts [2] - The report suggests monitoring companies in the copper mining and smelting sectors, such as China Nonferrous Mining (1258.HK) and Luoyang Molybdenum (3993.HK), due to rising copper prices driven by demand from AI data centers and electric vehicles [9]

港股创新药连续调整吸引资金关注，12月12日，核心标的港股通创新药ETF（520880）场内价格下探近 5个月低点，场内宽幅溢价，彰显买盘势力！此前4日已有资金连续进场，累计增仓逾1.3亿元。 | 册 多日 1分 * | | | | F9 盘前盘后 盈加 九转 图技 工具 @ 0 | | | | | | | 港股通创新药ETF O | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.544 | | | 520880[種設通创新的ETF] 10:20 价 0.537 涨跌 -0.001(-0.19%) | | | 1.12% | | | 0.537 -0.001 -0.19% | | 520880 | | | | 0.543 | | | | | | 0.93% | | | SSE CNY 10:20:39 交易中 查看L2全国 | | | T+0 De / 0 + | | | | | | | | | | 净值市势 | | 华宜恒生港股通创新商 | | 实时中购藏网体息申购 ...

Group 1: Industry Developments - Jiangsu Province has officially released its 15th Five-Year Plan, emphasizing the enhancement of industries such as biomedicine, new generation information technology, and high-end equipment, aiming to cultivate strategic emerging industry clusters with international competitiveness [1] - The global first CDK2/4/6 inhibitor, Kimosir, developed by China National Pharmaceutical Group's subsidiary, has been approved for marketing, marking a significant advancement in targeted therapy for breast cancer in China [1] - The innovative drug, Simoziran, developed by Shanghai Pharmaceuticals, has been approved for the treatment of primary hypertension, representing a new addition to the hypertension treatment market [2] Group 2: Company Announcements - Health元 has received a drug registration certificate for its innovative anti-influenza drug, Marpacisavir, which is effective for treating influenza A and B in adolescents and adults, showcasing significant advantages in efficacy and safety [3] - Baijun Medical's subsidiary has received approval for its collagen implant product, the first of its kind in China for improving facial smoothness, highlighting the company's innovation in the collagen field [4] - Innovent Biologics has announced the approval of its next-generation TRK inhibitor, Zoltritinib, for treating adult and adolescent patients with NTRK fusion gene solid tumors, marking a milestone in China's oncology market [5] Group 3: Market Movements - Saili Medical has reported a reduction in shareholding by Shanghai Anze Private Equity Fund to 5.00%, indicating a strategic shift in investment [6][7] - Newnow has submitted an application for H-share listing on the Hong Kong Stock Exchange, reflecting the trend of innovative pharmaceutical companies seeking dual listings [8] - Yunding New Medicine has entered into strategic cooperation with Haishen Biopharmaceuticals, enhancing its commercialization capabilities in the cardiovascular field through service and licensing agreements [9]

Core Viewpoint - China National Pharmaceutical Group announced that its subsidiary, Chengdu Tianqing, received approval for the CDK2/4/6 inhibitor, Kemosir Capsule (brand name: Saitanxin), for the treatment of HR+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy [1] Group 1: Product Development and Market Position - The company is expanding the indications for Kemosir, including first-line treatment for HR+/HER2- advanced breast cancer in combination with Fulvestrant and adjuvant therapy for HR+ early breast cancer [1] - The breast cancer treatment market is growing, becoming one of the most competitive areas for innovative drugs globally [1] - The company has established a comprehensive portfolio in the breast cancer field, covering various molecular subtypes such as HER2 positive (HER2+), low HER2 expression, HR positive (HR+/HER2-), and triple-negative breast cancer (TNBC) [1] Group 2: Comprehensive Treatment Coverage - The company systematically covers the entire treatment cycle for breast cancer, including adjuvant therapy, first-line, second-line, and neoadjuvant treatment scenarios, aiming to provide new treatment options for more patients [1] - In addition to Kemosir in the HR+/HER2- field, the company has differentiated products such as TQB2102 (HER2 dual antibody ADC), TQB3126 (ER-PROTAC), and TQB3202 (PI3Kα) [1] - The company has fully established a portfolio of mainstream foundational drugs for breast cancer, including already marketed products such as Qingkeyi (Fulvestrant injection), Qingweishi (Everolimus tablets), Saituo (Trastuzumab injection), Paletan (Pertuzumab injection), and Qingweiyi (Palbociclib capsules) [2]